Summary DT-diaphorase is a two-electron-reducing enzyme that is an important activator of bioreductive anti-tumour agents, such as mitomycin C (MMC) and E09, and is inducible by many compounds, including 1,2-dithiole-3-thiones (D3Ts). We showed previously that D3T selectively increased DT-diaphorase activity in mouse lymphoma cells compared with normal mouse marrow cells, and also increased MMC or E09 cytotoxic activity in the lymphoma cells with only minor effects in the marrow cells. In this study, we found that D3T significantly increased DT-diaphorase activity in 28 of 38 human tumour cell lines representing ten tissue types with no obvious relationships between the tumour type, or the base level of DT-diaphorase activity, and the ability of D3T to increase the enzyme activity. Induction of DT-diaphorase activity in human tumour cell lines by 12 D3T analogues varied markedly with the D3T structure. D3T also increased DT-diaphorase activity in normal human bone marrow and kidney cells but the increases were small in these cells. In addition, D3T increased the level of enzyme activity in normal human lung cells. Pretreatment of human tumour cells with D3T analogues significantly increased the cytotoxic activity of MMC or E09 in these cells, and the level of enhancement of anti-tumour activity paralleled the level of DT-diaphorase induction. In contrast, D3T did not effect the toxicity of E09 in normal kidney cells. These results demonstrate that D3T analogues can increase DT-diaphorase activity in a wide variety of human tumour cells and that this effect can enhance the anti-tumour activity of the bioreductive agents MMC and E09.
NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) (EC 1.6.99 .2) is a flavoprotein that catalyses obligatory two-electron reduction of quinones, quinone imines, azo dyes and nitrogen oxides (Riley and Workman, 1992) . The enzyme is found in all eukaryotes and is present at varying levels in most tissues (Benson et al, 1980; Belinsky and Jaiswal, 1993) . DT-diaphorase is located mainly in the cytosol, but 5-10% is membrane bound in mitochondria, microsomes and Golgi apparatus (Riley and Workman, 1992) . The enzyme has two identical subunits with individual molecular weights of 32 kDa and requires NADH or NADPH as an electron donor for enzymatic activity (Riley and Workman, 1992) . Several DT-diaphorases have been identified in humans (Jaiswal et al, 1990; Jaiswal, 1991) , but the NQO, gene has been most extensively studied and appears to be most important for activation of bioreductive anti-tumour agents (Jaiswal, 1991; Riley and Workman, 1992; Belinsky and Jaiswal, 1993) . Enzyme levels have been shown to be relatively high in mouse and/or human stomach, bladder, intestine, colon and kidney, but are usually low in liver, lung and haematopoietic cells (Benson et al, 1980; Schlager and Powis, 1990; Smitskamp-Wilms et al, 1995) . DT-diaphorase activity is higher in some tumour cells than in the corresponding normal cells, with elevated levels of enzyme activity having been observed in human liver, colon, breast and lung tumour cells (Schlager and Powis, 1990; Malkinson et al, 1992; Belinsky and Jaiswal, 1993; Smitskamp-Wilms et al, 1995) .
DT-diaphorase is a phase II detoxifying enzyme that is involved in metabolizing xenobiotics and carcinogens, thereby protecting the cell from their toxic and mutagenic effects (Beyer et al, 1988; Riley and Workman, 1992) . There has been considerable interest in the role of this enzyme, and other phase II enzymes, such as glutathione S-transferases (GST), epoxide hydrolase and UDPglucuronosyltransferases, in early cellular defence mechanisms against tumorigenesis (Beyer et al, 1988; Prestera et al, 1993) . DTdiaphorase is induced in many tissues by a wide variety of structurally dissimilar chemicals, including 1,2-dithiole-3-thiones (D3Ts), quinones, diphenols, phenylenediamines, Michael reaction acceptors, isothiocyanates and heavy metals (Prestera et al, 1993) . Thus, studies have investigated the use of inducers of DTdiaphorase and other phase II detoxifying enzymes in cancer prevention (Kelloff et al, 1990 ; Kensler and Helzlsouer, 1995) . Oltipraz, a D3T analogue used for treatment of schistosomiasis (Bueding et al, 1982) , is an inducer of phase II detoxifying enzymes (Kensler et al, 1992; Egner et al, 1994; Kensler and Helzlsouer, 1995) and inhibits development of tumours in animals (Kelloff et al, 1990 ; Kensler et al, 1992 ; Kensler and Helzlsouer, 1995) . This agent has low toxicity in animals and is in phase I and II clinical trials as a chemoprotective agent in humans (Kensler et al, 1992; Maxuitenko et al, 1996; O'Dwyer et al, 1996) . Because of their ability to induce phase II enzymes and their relatively low toxicity, other D3T analogues are also being investigated as cancer preventative agents (Egner et al, 1994) .
DT-diaphorase has been shown to be an important activating enzyme for bioreductive anti-tumour agents, such as mitomycin C (MMC) (Begleiter et al, 1989; Ross et al, 1993; Mikami et al, 1996), 3-hydroxymethyl-5-aziridinyl-l-methyl-2(1H-indole-4,7-dione) prop-,B-en-a-ol (EO9) (Plumb et al, 1994) , diaziquone (Siegel et al, 1990) , streptonigrin (Beall et al, 1996) and others (Workman and Stratford, 1993) in many systems. Bioreductive agents require intracellular activation by either two-electronreducing enzymes, such as DT-diaphorase (Ross et al, 1993; Plumb et al, 1994) and xanthine dehydrogenase (EC 1.1.1.204) (Gustafson and Pritsos, 1992) or by one-electron-reducing enzymes, such as NADPH:cytochrome P450 reductase (EC 1.6.2.4) (Pan et al, 1984) and NADH:cytochrome b5 reductase (EC 1.6.2.2) (Hodnick and Sartorelli, 1993) . In general, cell lines (Begleiter et al, 1989; Malkinson et al, 1992; Ross et al, 1993; Mikami et al, 1996) or tumour specimens (Nishiyama et al, 1993) with higher levels of DT-diaphorase are more sensitive to MMC. A significant correlation was found between the level of DTdiaphorase activity and sensitivity to MMC and E09 in the human tumour cell lines of the National Cancer Institute Tumour Cell Line Panel (Fitzsimmons et al, 1996) . E09 activity appears to be particularly sensitive to the level of DT-diaphorase under oxygenated conditions (Plumb et al, 1994) . Increasing DTdiaphorase activity in gastric carcinoma (Mikami et al, 1996) or Chinese hamster ovary cells (Belcourt et al, 1996) , by transfection of the NQO, gene, increased the sensitivity of the cells to MMC. In contrast, transfection of the NQO, gene into NIH 3T3 mouse fibroblasts did not increase MMC activity in these cells . In addition, DT-diaphorase did not appear to play a major role in activation of MMC in some cell lines in vivo (Nishiyama et al, 1993) or under hypoxia (Begleiter et al, 1992; Belcourt et al, 1996) . Furthermore, DT-diaphorase did not effect the toxicity of the benzotriazine di-N-oxide, tirapazamine (Patterson et al, 1994) and protected cells from the toxicity of the quinone agents, menadione (Atallah et al, 1988) , hydrolysed benzoquinone mustard, benzoquinone mustard and benzoquinone dimustard (Begleiter and Leith, 1990) .
A study by Shao et al (1995) found that high levels of dietary fish oil lowered the growth rate of MX-1, human mammary carcinoma, xenografts in athymic mice and increased DT-diaphorase activity in the tumour. The high levels of fish oil also increased the response of the tumour to MMC. We have previously shown (Begleiter et al, 1996 ) that D3T selectively increased the level of DT-diaphorase activity in L5178Y murine lymphoma cells with no effect on the activity of this enzyme in normal marrow cells from DBA/2 mice. Combination treatment of L5178Y tumour cells with D3T and MMC produced a twofold increase in cytotoxic activity compared with MMC alone. Similar treatment with D3T and E09 produced a sevenfold increase in anti-tumour activity compared with E09 alone. By comparison, D3T did not enhance the activity of MMC in normal mouse marrow cells and produced only a small increase in E09 cytotoxicity in these cells. The DT-diaphorase inhibitor dicoumarol inhibited the effect of D3T on the antitumour activity of the bioreductive agents, supporting the proposal that the enhanced anti-cancer activity was due to the elevated level of enzyme activity.
These findings suggest that inducers of DT-diaphorase, such as D3T analogues, may be useful to enhance the anti-tumour efficacy of bioreductive anti-tumour agents. Although induction of DTdiaphorase by D3T analogues has been studied previously in rodent tissues in the context of cancer chemoprevention, in this study we investigated the ability of D3T analogues to increase the level of DT-diaphorase activity in human tumour and normal cells as a way of enhancing the anti-tumour activity of bioreductive agents. We examined induction of the enzyme in tumour cell lines from different tissues and in cell lines having different base levels of DT-diaphorase. It has been shown previously (Egner et al, 1994 ) that induction of DT-diaphorase in mouse hepatoma cells was dependent on the chemical structure of the D3T analogue. Thus, we also investigated the ability of D3T analogues to induce DT-diaphorase activity in human tumour cell lines to identify structure-activity relationships that might be useful for developing more potent and selective enzyme inducers. Finally, we evaluated the effect of combining D3T analogues with MMC or E09 on the cytotoxic activity of these bioreductive anti-tumour agents in human tumour and normal cell lines.
MATERIALS AND METHODS Materials
All media, fetal bovine serum (FBS) and insulin transferrin selenium (ITS) were obtained from Gibco BRL (Grand Island, NY, USA). All reagents for the DT-diaphorase assay, hydrocortisone, Ficoll 400, lactalbumin hydrosylate, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and MMC were from Sigma (St Louis, MO, USA). E09 was kindly supplied by Dr HR Hendriks, New Drug Development Office, European Organization for Research and Treatment of Cancer, Amsterdam, The Netherlands. MMC was dissolved in phosphate-buffered saline (PBS), while E09 was dissolved either in dimethyl sulphoxide (DMSO) or v:v) . The final concentration of DMSO or ethanol did not exceed 1%. The D3T analogues were synthesized by Dr TJ Curphey. D3T analogues were prepared in ethanol at a concentration of 2 x 10-2 M with the exceptions of ADT, which was prepared at 1 x 10-2 M in ethanol, and Oltipraz, which was prepared at 2 x 10-2 M in DMSO or at 5 x 10-3 M in acetone. The final concentration of acetone did not exceed 2% and that of DMSO or ethanol did not exceed 1% in the cell incubation media. Appropriate media and FBS at pH 7.2 were used for all DTdiaphorase induction studies and incubations with MMC or E09.
Induction of DT-diaphorase in human tumour cell lines 1243 Normal marrow specimens were obtained from marrow donated for transplantation and mononuclear cells were isolated using a FicollHypaque gradient (Johnston et al, 1994 
Induction of DT-diaphorase
Exponentially growing cells were treated with D3T analogues at 37°C for various periods of time. Cells were washed, pelleted, suspended in 100-200 gl of 0.25 M sucrose, sonicated and stored at -80°C. DT-diaphorase activity was measured, using menadione as the electron acceptor, by the assay of Prochaska and Santamaria (1988) , modified for use in a semi-microcuvette. Briefly, 5-100 ±g of protein was assayed for DT-diaphorase activity by adding the appropriate volume of sucrose sonicate to a semi-microcuvette containing 750 g1 of the assay stock solution (Prochaska and Santamaria, 1988) . The increase in absorbance at 25°C at 610 nm was followed for up to 10 min using a Cary I spectrophotometer. Duplicate cuvettes were prepared for each sample, one for total activity and one with 10 gM dicoumarol. The DT-diaphorase activity reported was the dicoumarol-inhibitable activity. DTdiaphorase activity was expressed as nmol MIT min-' mg-' protein. Enzyme activities as low as 1.0 nmol MTT min-' mg-' protein could be detected with this assay procedure. Protein concentration was measured using the Bio-Rad DC Kit (Bio-Rad, Mississauga, Canada) with gamma globulin as standard. The concentrations of the D3T analogues used in these studies produced little or no toxicity to the cells during the incubation period.
Measurement of GST activity GST activity was tneasured in the supernatant of cell sonicates by a previously described spectrophotometric procedure (Habig et al, 1974 ) using 1-chloro-2,4-dinitrobenzene as substrate.
Measurement of NADPH:cytochrome P450 reductase activity NADPH-cytochrome P450 reductase activity was determined in supematants from cell sonicates by a spectrophotometric assay using cytochrome c as the artificial electron acceptor (Strobel and Digman, 1978) .
Measurement of NADH:cytochrome b5 reductase activity
NADH:cytochrome b5 reductase activity was determined spectrophotometrically using the method of Barham et al (1996) , which measures the pHMB-inihibitable, NADH-dependent reduction of cytochrome c.
British Journal of Cancer (1998) 77 (8), 1241-1252 pelleted, suspended in 100-200 li of 0.25 M sucrose, sonicated and stored at -800C. DT-diaphorase activity was measured as described in Matenals and methods using menadione as the electron acceptor. The data represent the mean ± standard error of 3-15 determinations. Statistical significance was determined using a two-tailed t-test comparng the significance of the difference of the mean DT-diaphorase activity in control and D3T-treated cells.
Measurement of xanthine dehydrogenase activity
Xanthine dehydrogenase activity was determined using the spectrophotometric method of Gustafson et al (1991) . This method follows the formation of uric acid from xanthine in the presence and absence of NAD+ to distinguish the xanthine dehydrogenase and xanthine oxygenase forms of the enzyme.
Cytotoxicity studies HL-60, human promyelocytic leukaemia cells, or 293, human normal kidney cells, were incubated with or without 50 gM D3T or 50 S M Oltipraz for 48 h and then were treated with various concentrations of E09 for 1 h. The surviving cell fraction for HL-60 cells was determined by clonogenic assay (Begleiter et (Table 1) . Tumour cell lines from ten different tumour types were studied, including leukaemia, head and neck, lung, colon, stomach, breast, ovary, prostate, melanoma and liver. The base level of DT-diaphorase activity in the cells ranged from < 1.0 to 2120 nmol MTT min-' mg-' protein. Enzyme activity was significantly increased with D3T incubation in 28 of the cell lines, with the increase ranging from 1.2-to 8.0-fold, or from 2.5 to 590 nmol MTT min-1 mg-' protein in absolute terms. Cells from all tumour types appeared to be inducible with the exception of head and neck and liver tumours. Four of five lung tumour cell lines showed increased DT-diaphorase activity after incubation with D3T, and this included both small-cell and non-small-cell lung tumours. Six of nine breast carcinoma cell lines were inducible by D3T, with most of the cell lines having intermediate base levels of DTdiaphorase being induced. Oestrogen receptor status did not appear to influence enzyme induction as three of the induced breast cancer cell lines were oestrogen receptor positive and three were oestrogen receptor negative. Similarly, D3T increased DT-diaphorase activity in two of three prostate carcinoma cell lines; one induced cell line was androgen receptor positive, while the other was androgen receptor negative. Four of five colon tumours and all the malignant melanoma cell lines studied showed significantly increased levels of DT-diaphorase activity after treatment with D3T, despite the fact that many of these cells had very high base levels of enzyme activity. D3T also increased DT-diaphorase activity in all the leukaemias, stomach tumours and ovarian tumours studied. (Begleiter et al, 1989) . The points represent the mean surviving cell fraction ± standard error of 6-13 determinations. The lines are linear regression lines. Inset, level of DT-diaphorase activity in control and cells treated with Oltipraz or D3T. The bars represent the mean DT-diaphorase activity ± standard error of four to ten determinations. The means were compared using a t-test evaluating the significance of the difference of the DT-diaphorase activity in the control and D3T analogue-treated cells
DT-diaphorase induction by D3T analogues
The structures of the D3T analogues used in this study are shown in Figure 2 . The analogues had substituents at either or both the 4-and 5-positions of the disulphide ring structure. Some of the analogues had unique features to their structure. Analogue 8 had a S-oxide on the thione group; analogue 9 had a structure that corresponded to a possible opened-ring metabolite of D3T, and analogue 10 was the only compound that had a salt structure. The ability of the D3T analogues to induce DT-diaphorase activity was examined in eight cell lines from five tissue types: two leukaemia cell lines, HL-60 and THP-1; two lung carcinoma cell lines, NCI-H661 and NCI-H209; two colon carcinoma cell lines, LS174T and HT29; one liver tumour cell line, HepG2; and one breast cancer cell line, MCF-7. Cells were incubated with 100 JM of each inducer for 48 h. The control and induced DT-diaphorase enzyme activity levels for these cell lines are summarized in Table 2 .
The base levels of DT-diaphorase activity in HL-60 and THP-l were 4.5 ± 0.5 and 26.1 ± 2.3 nmol MTT min-1 mg-' protein respectively (Table 2 ). For the HL-60 cell line, 11 of the 13 analogues significantly induced DT-diaphorase activity, with the induced levels of DT-diaphorase activity ranging from 7.4 ± 0.8 to 38.4 ± 5.8 nmol MTT min-' mg-' protein. The best inducers of DTdiaphorase in the HL-60 cells were analogue 7, D3T, analogue 9 and Oltipraz. In the THP-l cell line, 12 of the 13 analogues significantly induced DT-diaphorase activity. DT-diaphorase activity in induced cells ranged from 38.4 ± 6.3 to 124.2 ± 11.6 nmol MTT min-' mg-' protein. The best inducers in the THP-1 cells were analogue 7, D3T and analogue 8.
The NCI-H209 and NCI-H661 cell lines had base DTdiaphorase activities of 8.3 ± 0.8 and 112.7 ± 12.4 nmol MTT min-1 mg-' protein respectively. In the NCI-H209 cells, significant induction occurred with only 4 of the 13 analogues, D3T, analogue 7, analogue 9, and analogue 4, and the induced activity ranged from 13.6 ± 2.4 to 40.2 ± 3.1 nmol MTT min-' mg-' protein. In the NCI-H661 cell line, 9 of the 13 analogues significantly induced DT-diaphorase activity. The induced enzyme levels varied from 168.0 ± 26.8 to 309.9 ± 58.9 nmol MTT min-' mg-' protein.
The best DT-diaphorase inducers were analogue 7, analogue 9 and D3T.
LS174T and HT29 had control DT-diaphorase activities of 314.6 ± 39.0 and 713.1 ± 47.4 nmol MTT min-' mg-' protein respectively. In the LS 174T cell line, 11 of the 13 analogues increased DT-diaphorase activity levels significantly. Induced levels varied from 482.7 ± 29.6 to 776.0 ± 97.5 nmol MTT min-' mg-' protein. The best inducers were D3T, analogue 9, analogue 3 and analogue 4. Only three analogues significantly induced DTdiaphorase activity in the HT29 cell line. The induced enzyme levels ranged from 907.7 ± 78.5 to 1110.5 ± 87.4 nmol MTT minmg-' protein for analogue 5, D3T and analogue 8.
The base level of enzyme activity in the MCF-7 breast carcinoma cells was 939.1 ± 88.3 nmol MTT min-1 mg-' protein, and none of the D3T analogues increased DT-diaphorase activity significantly. The control level of DT-diaphorase activity in the hepatoma cell line HepG2 was also high, with a level of 1292.5 ± 162.0 nmol MTT min-1 mg-' protein, and no significant induction of enzyme activity was observed with exposure to any of the D3T analogues.
Induction of DT-diaphorase in human normal cells
The base level of DT-diaphorase activity in human bone marrow cells was very low, 1.2 ± 0.4 nmol MIT min-1 mg-' protein; however, incubation with D3T resulted in a small, but significant increase in this activity to 12.7 ± 2.4 nmol MTT min-' mg-' protein (P < 0.005) ( Table 3 ). The base level of enzyme activity in 293 human kidney cells was also very low, 2.2 ± 0.3 nmol MTT min-] mg-' protein, and D3T also increased DT-diaphorase activity in these cells to 7.7 ± 0.1 nmol MTT min-1 mg-' protein (P < 0.001). In contrast, WI-38 human lung cells had an intermediate base level of DT-diaphorase activity, 76.5 ± 6.5 nmol MIT min-' mg-' protein, and this was increased to 182.3 ± 12.2 nmol MTT min-' mg-' protein (P < 0.002) by treatment with D3T. (P < 0.001) or 15.6 ± 1.5 (P < 0.001) nmol MTT min-' mg-' protein respectively. Pretreatment with Oltipraz enhanced the cytotoxicity of E09 in HL-60 cells with the Do decreasing from 6.1 ± 0.5 gM to 4.3 ± 0.3 gM (P < 0.02). Pretreatment with D3T also increased the cytotoxicity of E09 with the Do decreasing from 6.1 ± 0.5 gM to 3.3 ± 0.2 gM (P < 0.001), and this effect was significantly greater than the effect observed with Oltipraz (P < 0.05).
The addition of the DT-diaphorase inhibitor, dicoumarol, before treatment with E09 reversed the increased cytotoxicity with D3T (P < 0.005). In contrast, when 293 human normal kidney cells were treated with 50 gM D3T for 48 h, there was no significant increase in DT-diaphorase activity compared with control cells, and the cytotoxic activity of E09 in these cells (Do = 31.7 ± 2.5 gM, determined by MTT assay) did not change significantly when the cells were pretreated with D3T ( Figure 4 ).
H661 cells were incubated with or without 50 gM analogue 8 or 50 gM D3T for 48 h and then were treated with various concentrations of E09 for 1 h. Cytotoxicity was determined by MTT assay ( Figure 5 ). Treatment of H661 cells with 50 gM analogue 8 or 50 gM D3T increased DT-diaphorase activity from 168.4 ± 15.6 to 226.8 ± 17.9 (P < 0.05) or 266.7 ± 43.6 nmol MTT min-' mg-' protein respectively. Pretreatment with analogue 8 or D3T enhanced the cytotoxicity of E09 in H661 cells with the Do decreasing from 0.7 ± 0.1 gM to 0.5 ± 0.1 0.1 JM (P < 0.05) or 0.5 ± 0.1 JIM (P < 0.05), respectively, but the effect of D3T was not significantly different from that of analogue 8.
T47D human breast cancer cells were incubated with or without 75 JM D3T for 48 h and then were treated with various concentrations of MMC for 1 h. Cytotoxicity was determined by MTT assay (Figure 6 ). Incubation of the cells with D3T increased the level of DT-diaphorase activity from 25.8 ± 1.0 to 96.9 ± 5.6 nmol MTT min-' mg-' protein (P < 0.001) and also significantly enhanced the cytotoxicity of MMC by threefold. The Do decreased from 3.8 ± 0.1 JM for MMC alone to 1.2 ± 0.1 JM with D3T (P < 0.001).
DISCUSSION
DT-diaphorase is a highly inducible enzyme that can be an important activating enzyme for bioreductive anti-tumour agents (Riley and Workman, 1992; Ross et al, 1993) . The enzyme has also been shown to play an important role in detoxifying chemically reactive metabolities in cells, thus protecting the cell from their toxic and mutagenic effects (Beyer et al, 1988; Riley and Workman, 1992) . Recent studies have investigated the use of inducers of DTdiaphorase in cancer prevention (Kelloff et al, 1990; Kensler et al, 1992; O'Dwyer et al, 1996) . However, there have been few investigations of the potential use of inducers of DT-diaphorase to enhance the anti-tumour activity of anti-tumour agents that are activated by this enzyme. Shao et al (1995) found that the fish oil menhaden oil increased DT-diaphorase activity in an MX-1, human mammary carcinoma, tumour grown in athymic mice and also increased the response of the tumour xenograft to MMC. We have shown that D3T, an inducer of DT-diaphorase, can increase the level of DT-diaphorase activity in murine lymphoma cells without altering the level of enzyme activity in normal murine marrow cells, resulting in an increase in the anti-tumour activities of MMC and E09 (Begleiter et al, 1996) . In this study, we investigated the ability of D3T analogues to induce DT-diaphorase in different human tumour types and examined the ability of these analogues to enhance the cytotoxic activity of the bioreductive agents E09 and MMC in human tumours.
The results of this study demonstrated that D3T can increase the level of DT-diaphorase activity in most human tumour cell types. Overall, 28 of 38 tumour cell lines showed significant increases in enzyme activity after treatment with 100 JM D3T that ranged from 1.2-to 8.0-fold, or from 2.5 to 590 nmol MTT min-m mg-1 protein in absolute terms (Table 1) . Leukaemia, lung, colon, stomach, breast, ovary, prostate and melanoma tumour cells lines were all inducible. In contrast, three head and neck tumours and one liver tumour were not induced by D3T. In addition, some tumour types appeared to be more readily induced. For example, all the leukaemia cell lines were induced, as were all the gastric tumour, ovarian tumour and malignant melanoma cell lines. However, the differences in inducibility of DT-diaphorase activity in the different cell types may simply reflect the particular cell lines of the tumour types examined in this study.
The mechanisms responsible for the differences in DTdiaphorase induction in different cell lines are unknown. Regulation of expression of DT-diaphorase activity is complex and may include regulation of transcription (Jaiswal, 1991; Belinsky and Jaiswal, 1993; Yao and O'Dwyer, 1995; Wang and Williamson, 1996) , altemative splicing of DT-diaphorase mRNA Hu et al, 1996; Yao et al, 1996) and the presence of a polymorphism due to a mutation at position 609 of British Journal of Cancer (1998) 77(8) at 370C with or without 50 gM D3T for 48 h. Cells were then treated with various concentrations of E09 for 1 h. Surviving cell fraction was determined by MUT assay (Johnston et al, 1994) . The points represent the mean surviving cell fraction ± standard error of five determinations. The lines are linear regression lines. Inset, level of DT-diaphorase activity in control and cells treated with D3T. The bars represent the mean DT-diaphorase activity ± standard error of four determinations. The means were compared using a t-test evaluating the significance of the difference of the DT-diaphorase activity in the control and D3T-treated cells the NQO1cDNA (Traver et al, 1992; Kuehl et al, 1995) that results in a protein with very low enzyme activity (Traver et al, 1997) . Whether any of these mechanisms are responsible for the different effects of the D3T analogues on DT-diaphorase activity in the different human cell lines studied remains to be determined. There was no obvious relationship between the base level of DT-diaphorase activity in the tumour cells and the ability of D3T to increase enzyme activity. Although four of the ten tumour cell lines that were not induced by D3T had high base levels of DTdiaphorase activity, all the melanoma tumours, and other cell lines, that had high base levels of enzyme activity were induced. While the increase in enzyme activity relative to the base level was low in these cells, the absolute increase in enzyme activity was very high. In addition, the oestrogen or androgen receptor status of the cells did not appear to affect the induction of DT-diaphorase. Of the six breast cancer cell lines that were induced by D3T, three were oestrogen receptor positive and three were oestrogen receptor negative. Similarly, one of the two prostate cell lines that were induced by D3T was androgen receptor positive while the other was androgen receptor negative.
DT-diaphorase induction by D3T and 12 analogues was examined in five different tumour tissue types to identify any tissuespecific DT-diaphorase induction profiles. Overall, the D3T analogues did not appear to show any obvious tissue specificity for Figure 5 Effect of analogue 8 or D3T on cytotoxic activity of E09 and DTdiaphorase activity in H661, human large-cell lung tumour cells. Cells were incubated at 370C with or without 50 gM analogue 8 or 50 gM D3T for 48 h. Cells were then treated with various concentrations of E09 for 1 h. Surviving cell fraction was determined by MTT assay (Johnston et al, 1994) . The points represent the mean surviving cell fraction ± standard error of seven to nine determinations. The lines are linear regression lines. Inset, level of DTdiaphorase activity in control and cells treated with analogue 8 or D3T. The bars represent the mean DT-diaphorase activity ± standard error of four determinations. The means were compared using a t-test evaluating the significance of the difference of the DT-diaphorase activity in the control and D3T analogue-treated cells enzyme induction. However, some of the D3T analogues were better inducers of DT-diaphorase than others in the human tumour cell lines examined, and this may indicate some structure-activity relationships. The parent compound, D3T, was the most consistent inducer, producing significant increases in enzyme activity in six of the eight cell lines. Analogues 4, 5, 7, 8 and 9 were also consistent inducers of DT-diaphorase activity, producing significant increases in enzyme activity in five cell lines. Of these, D3T and analogues 7, 8, and 9 generally produced the largest increases in DT-diaphorase activity. In contrast, analogue 10 was the poorest inducer in the cell lines studied. These results suggest that the parent D3T is the best inducer of DT-diaphorase activity of the analogues studied. However, the carbamoyl group in analogue 7, the S-oxide in analogue 8 and the ring-opened structure in analogue 9, in some instances, may produce greater increases in DT-diaphorase activity than D3T. These studies do not indicate any apparent difference in induction capacity between analogues with substituents at position 4 or 5 of the D3T ring, but the salt structure in analogue 10 may reduce induction capacity, possibly as a result of decreased cellular uptake. Talalay (1989) MUT assay (Johnston et al, 1994 Egner et al (1994) compared the induction of DT-diaphorase in Hepa lclc7, mouse hepatoma cells, by 25 D3T analogues. This group of analogues included D3T, Oltipraz, analogues 1-6, and analogue 8, which we also examined in our study. Consistent with our findings, D3T was one of the more potent DT-diaphorase inducers in the Hepa Ic Ic7 cells. In addition, the 5-ethyl analogue (analogue 4) and the S-oxide analogue (analogue 8) were relatively potent inducers in both studies. In contrast, the 4-ethyl analogue (analogue 3), the 4-phenyl analogue (analogue 6) and the 5-t-butyl analogue (analogue 5) were good inducers in Hepa c c7 cells but poor inducers in the human tumour cell lines.
Furthermore, the ring-opened analogue (analogue 9) was a good inducer of DT-diaphorase in human tumours, but a ring-opened analogue of Oltipraz was inactive in the mouse hepatoma cells.
Comparison of the results of these two studies indicate both similarities and differences in induction of DT-diaphorase by D3T analogues in human and mouse tumour cells. Whether these relate to species differences or differences in tumour type is unknown.
The base levels of DT-diaphorase activity were very low in the normal marrow and kidney cells that we examined. While D3T produced significant increases in enzyme activity in these cells, the actual increases were only 11.5 and 5.5 nmol MTT min-' mg-' protein, respectively, less than half the increase observed in HL-60 leukaemia cells. In contrast, D3T increased the level of DTdiaphorase activity in normal human lung cells by 2.4-fold.
Combination treatment with Oltipraz or D3T and E09 increased the anti-tumour activity of E09 in HL-60, human promyelocytic leukaemia cells (Figure 3 ). Oltipraz and D3T increased the level of DT-diaphorase activity in these cells by 1.7-and 4.7-fold, respectively (P < 0.001), and also increased the cytotoxic activity of E09 by 1.4-and 1.8-fold, respectively, in these cells (P < 0.02). The increased cytotoxic activity was due to the elevated DT-diaphorase activity, as dicoumarol, an inhibitor of the enzyme, reversed the effect of D3T on E09 cytotoxic activity (P < 0.005). In addition,
D3T did not increase the activities of NADPH:cytochrome P450 reductase, NADH:cytochrome b5 reductase or xanthine dehydrogenase, other enzymes that can activate bioreductive agents (Pan et al, 1984; Gustafson and Pritsos, 1992; Hodnick and Sartorelli, 1993) , in these cells. Pretreatment of H661, human non-small-cell lung cancer cells with analogue 8 or D3T significantly increased the cell kill observed with E09 by 1.5-and 1.6-fold respectively (P < 0.05) ( Figure 5 ). The enhancement of E09 cytotoxicity by the D3T analogues parallelled their effect on induction of DT-diaphorase. Thus, other D3T analogues that produce greater induction of DTdiaphorase activity may further enhance the cytotoxic activity of bioreductive agents. Similarly, combination treatment with D3T and MMC increased the anti-tumour activity of MMC in T47D, human breast carcinoma cells (Figure 6) . D3T increased the level of DT-diaphorase activity in these cells by 3.8-fold (P < 0.001) and also increased the cytotoxic activity of MMC by threefold in these cells (P < 0.001).
The major toxicities observed with MMC and E09 are bone marrow and kidney toxicity respectively (Hortobagyi, 1993; Schellens et al, 1994) . Treatment with 100 gM D3T produced small, but significant, increases in the levels of DT-diaphorase activity in normal human marrow and kidney cells. Because the increases in DT-diaphorase activities were very small in these cells, it is unlikely that the toxicity to these cells would be significantly increased. Indeed, 50 gM D3T did not effect the toxicity of E09 in the human normal kidney cells, but this concentration of D3T did not significantly increase DT-diaphorase activity in the kidney cells. Furthermore, we have shown previously that D3T did not increase the toxicity of MMC to mouse marrow cells (Begleiter et al, 1996) . In contrast, the increase in enzyme activity in the normal human lung cells was considerably larger. This effect might increase MMC toxicity to normal lung tissues in a clinical setting. However, MMC has been shown to produce pulmonary fibrosis in approximately 5% of patients (Klein and Wilds, 1983 ) by a mechanism that probably involves redox cycling and the formation of reactive oxygen species. Thus, it is possible that the increase in DT-diaphorase activity in normal lung cells with D3T treatment may serve to decrease this lung toxicity, as two-electron reduction of MMC to its hydroquinone by DTdiaphorase would decrease reactive oxygen species formation.
British Journal of Cancer (1998) The overall effect of DT-diaphorase induction on MMC toxicity in the lung will need to be assessed in an in vivo study.
These studies do not provide any conclusive evidence about the level of increase in DT-diaphorase activity that is required to increase the cytotoxic activity of the bioreductive anti-tumour agents. It is not known whether there is a threshold of induction that must be exceeded before the cytotoxic activity of the bioreductive agents is increased. For example, an increase in DTdiaphorase activity of 2.5 nmol MTT min-' mg-' protein in HL-60, human leukaemia cells, produced by 50 gM D3T, increased cell kill by E09 by 1.4-fold, while an increase in enzyme activity of 1.1 nmol MTT min-' mg-' protein in 293, human normal kidney cells, also produced by 50 gM D3T, had no effect on E09 activity in these cells. If there is a threshold level of DT-diaphorase induction required for an effect on the activity of bioreductive agents, it is still unclear whether this level will be the same for all cells or, as is more likely, the level will be different in different cells. Furthermore, it is not known whether the absolute level of increase in DT-diaphorase activity or the level of increase relative to the base level of enzyme activity is most important for determining the effect on the cytotoxic activity of the anti-tumour agents. Despite these ambiguities, this study demonstrates that non-toxic concentrations of D3T analogues can produce large increases in DTdiaphorase activity in a wide variety of human tumour cells and can enhance the anti-tumour activity of E09 and MMC with only small effects on normal kidney and marrow cells, which represent the most important sites of clinical toxicity to these bioreductive agents.
The GSTs are a family of phase II detoxifying enzymes that have been shown to be coordinately induced with DT-diaphorase in some tissues (Talalay, 1989) . These enzymes may also protect cells from the toxic and mutagenic effects of foreign chemicals (Prestera et al, 1993) . In addition, GSTs have been shown to play an important role in resistance to a variety of anti-tumour agents, including MMC, by aiding in the removal of the drugs from cells (Waxman, 1990; Xu et al, 1994) . Thus, if D3T were to increase the levels of both DT-diaphorase and GST activity in tumour cells, this might not result in a net increase in anti-tumour activity. This did not occur in our studies as we did observe an increase in antitumour activity with both E09 and MMC in three tumour cell lines. Furthermore, we did not see any increase in GST activity in HL-60 cells treated with D3T, as has been observed previously (Li et al, 1994) . Therefore, it appears that it is possible to increase DTdiaphorase activity in tumour cells without increasing GST. Additional studies are required to determine whether this effect is observed in other tumour cells, in normal tissues or with other inducers.
In summary, we have shown that D3T analogues significantly increased the level of DT-diaphorase activity in 28 of 38 human tumour cells representing a wide variety of tumour types. DTdiaphorase activity was also increased in normal human bone marrow and kidney cells, but the increases were small in these cases. D3T produced a significant increase in enzyme activity in normal human lung cells. Modifications to the basic D3T structure, such as the 5-carbamoyl substituent, the S-oxide function, or opening of the dithiolethione ring may increase the enzyme inductive capacity. D3T analogues that combine these structural features may prove to be better inducers of DT-diaphorase. Additional studies are required to identify D3T analogues that produce the optimum selective increase in DT-diaphorase activity in tumour cells compared with normal cells.
Combination treatment of human tumour cells with D3T
analogues and the bioreductive anti-tumour agents, MMC or E09, produced significant increases in cytotoxic activity in human tumour cells, and the level of enhancement of anti-tumour activity paralleled the level of DT-diaphorase induction. In contrast, D3T did not effect the toxicity of E09 in normal kidney cells. Thus, it may be possible to use inducers of DT-diaphorase to enhance the effectiveness of bioreductive anti-tumour agents that are activated by this enzyme. This approach appears to be applicable to different agents and in different tumour cells. The development of D3T analogues that are more potent and selective inducers of DTdiaphorase would increase the potential use of this therapeutic approach. Additional studies with other inducers, anti-tumour agents and cells are required to identify the optimum uses for this new treatment strategy.
